Company:  VERTEX PHARMACEUTICALS IN ... (VRTX)
Form Type:  10-Q
Filing Date:  7/30/2021 
CIK:  0000875320 
Address:  50 NORTHERN AVENUE 
City, State, Zip:  BOSTON, Massachusetts 02210 
Telephone:  (617) 341-6393 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$188.30  
Change: 
1.20 (0.64%)  
Trade Time: 
Sep 17  
Market Cap: 
$48.85B
Trade VRTX now with 

© 2021  
Description of Business
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets. Cystic Fibrosis Our goal is to develop treatment regimens that will provide benefits to all people with cystic fibrosis, or CF, and will enhance the benefits currently provided to people taking our medicines. Our marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Our triple combination regimen, TRIKAFTA/KAFTRIO, was approved in 2019 in the United States, or U.S., and in 2020 in the European Union, or E.U. Collectively, our four medicines are approved to treat the majority of the approximately 83,000 people with CF in North America, Europe and Australia.
Register and access this filing in:     
  FORM 10-Q
    Part I. Financial Information
      Item 1. Financial Statements
        INCOME STATEMENT
        BALANCE SHEET
        STOCKHOLDERS EQUITY
        CASH FLOW
        Notes to Condensed Consolidated Financial Statements (unaudited)
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures
    PART II. Other Information
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 2. Unregistered Sales of Equity Securities and Use of ...
      Item 6. Exhibits
    SIGNATURES
  EXHIBIT 10.1
  EXHIBIT 10.2
  EXHIBIT 10.3
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 31.2
    CERTIFICATION
  EXHIBIT 32.1
    SECTION 906 CEO/CFO CERTIFICATION